Constellium SE is currently undervalued despite posting record Q1 earnings and raising its full-year guidance. The company benefits from strong demand in aerospace and automotive lightweighting, a solid capital allocation strategy, and a new €300 million share buyback program. Q1 2024 saw a 78% year-over-year increase in adjusted EBITDA and margin expansion across all segments, although some gains were influenced by favorable metal price timing. While the outlook remains positive, investors should be cautious of cyclical challenges, potential metal price reversals, and risks in the European market that could affect medium-term growth.
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...
Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, ...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
DeFi platform Aave introduced Stable Vaults, enabling fintechs and payment providers to offer fixed-rate stablecoin yields, enhancing its ecosystem. This launch, alongside the Aave V4 upgrade, increased token trading volume by 14.5% and price by near...
Morgan Stanley has filed to launch Ethereum and Solana ETFs with a competitive 0.14% management fee, aiming to capture market share as crypto ETFs become more commoditized. These ETFs will offer direct token exposure, staking rewards, and institution...
